EFFECTS OF SELECTIVE GABA-A AGONISTS MODULATOR IN RATS WITH NEUROPATHIC PAIN

Neuropathic pain is the discomfort brought on by a condition that affects the sensory nerves. Dysesthesia and allodynia can both be brought on by damaged nerves. Zopiclone is a nonbenzodiazepine, regulating the GABA receptor, thus relaxes the nerves and brain. The role of glycinergic and γ-aminobutyric acid (GABA)ergic neurons in this process has been widely described. Benzodiazepine-sensitive GABAA receptors contain at least one of the following α subunits α1, α2, α3 or α5. In animals, α1-sparing (non-sedative) agonists showed an antihyperalgesic activity in inflammatory and neuropathic pain models without losing efficacy after repeated treatment. In the current investigation, zopiclone decreased allodynia and hyperalgesia brought on by models for Disease-Induced Neuropathy Pain (DINP), Paclitaxel-Induced Neuropathic Pain (PINP), and Chronic Constriction Injury (CCI). Its effect was dose-dependent, and one of its mechanisms of action was probably the sequential activation of spinal neurons at the supraspinal site of action. The current study further supports the likelihood that zopiclone will be helpful in the management of neuropathic pain, even if additional preclinical and clinical investigations are unquestionably necessary.